Literature DB >> 19077895

Transplantation of NIT-1 cells expressing pD-L1 for treatment of streptozotocin-induced diabetes.

Xue Wen1, Huifen Zhu, Li Li, Yan Li, Min Wang, Jing Liu, Daofeng Yang, Wenjun Liao, Guanxin Shen.   

Abstract

BACKGROUND: Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1 and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. In this study, we tested the effect of PD-L1-transfected pancreatic beta-cell line established from a transgenic NDD/Lt mouse (NIT) on the alloresponse and streptozotocin-induced diabetes.
METHODS: The diabetes model was established by a low dose of streptozotocin in Balb/C mice. PD-L1 transfected NIT cell line was established, namely NIT-PD-L1. NIT-1, empty vector-transfected NIT-1, or NIT-PD-L1 cells were transplanted into diabetic mice by intraperitoneal injection, respectively. Proliferation and apoptosis of splenic lymphocytes were detected by labeling with carboxy fluorescein succinimidyl ester or AnnexinV-Cy5 and proliferation index (PI). Cytokines were determined by enzyme-linked immunosorbent assay and flow cytometry analysis.
RESULTS: When compared with the controls, overexpression of PD-L1 on NIT-1 cells markedly prolonged allograft survival in diabetic mice. In mixed cells reaction, splenic lymphocytes from NIT-PD-L1-transplanted diabetic mice co-culture with mitomycin C-treated NIT-PD-L1 showed the lowest proliferative response but severe apoptosis. In addition, NIT-PD-L1 suppressed interferon-gamma but up-regulated interleukin-4 and -10 productions by those lymphocytes in vitro and in vivo.
CONCLUSION: Our data demonstrated that overexpression of PD-L1 on pancreatic beta cells significantly can prolong allograft survival, and it is associated with inhibition of lymphocytes activation and proliferation, induction of lymphocytes apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19077895     DOI: 10.1097/TP.0b013e31818c6e64

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

2.  Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes.

Authors:  Kin Man Au; Yusra Medik; Qi Ke; Roland Tisch; Andrew Z Wang
Journal:  Adv Mater       Date:  2021-05-08       Impact factor: 32.086

3.  PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice.

Authors:  Rongying Li; Jeongkyung Lee; Mi-sun Kim; Victoria Liu; Mousumi Moulik; Haiyan Li; Qing Yi; Aini Xie; Wenhao Chen; Lina Yang; Yimin Li; Tsung Huang Tsai; Kazuhiro Oka; Lawrence Chan; Vijay Yechoor
Journal:  Diabetes       Date:  2014-10-20       Impact factor: 9.461

Review 4.  Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases.

Authors:  Yujia Zhai; Reza Moosavi; Mingnan Chen
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

5.  Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.

Authors:  Kazunori Tokuda; Tetsuya Ikemoto; Shoko Yamashita; Katsuki Miyazaki; Shohei Okikawa; Shinichiro Yamada; Yu Saito; Yuji Morine; Mitsuo Shimada
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.